1. EBITDAW was (58.3m) and 8.9m in H1 and H2 respectively (FY = 49.4m loss). 36.6m is EBITDAW normalised so the one-off adjustments are 36.6 + 49.4 = 86m.
2. I think you are confusing with P/E multiples otherwise I'm not sure how an EBITAW multiple for the company in isolation of its peers and the market would give you any indication whether it is fair value.
- Forums
- ASX - By Stock
- SGH
- Ann: FY16 Earnings Guidance-SGH.AX
Ann: FY16 Earnings Guidance-SGH.AX, page-71
-
-
- There are more pages in this discussion • 388 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SGH (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online